Press Releases
AceBiome, Made Its First Entry Into Chinese Market through the Local Social Commerce Platform “Xiaoh
관리자 / 2024-09-02
AceBiome, Made Its First Entry Into Chinese Market through the Local Social Commerce Platform “Xiaohongshu”
- Launching “BNRThin” brand on “Xiohongshu” targeting Chinese consumers through promotion collaborations with the highly-regarded Korean actress Kim Hee-sun and local Influencers.
- By initiating this Chinese Market entry which the country is World’s largest obese population, the Company will continue its success story of Korea's No.1 diet probiotic “BNRThin”
AceBiome, a renowned health supplement company in South Korea, announced the official launch of “BNRThin” on China’s leading social commerce platform Xiaohongshu, marking its full-scale entry into the 16.67 billion USD Chinese probiotics market.
Xiaohongshu, a platform with over 300 million monthly active users, is a leading beauty and health social commerce platform in China, continuously expanding among young women born in the 1990s and 2000s. The company expects that the platform’s characteristic of enabling direct communication between sellers and consumers will help rapidly increase market awareness during the initial entry phase.
AceBiome plans to enhance communication with local consumers through Xiaohongshu, promoting the distinctiveness and functionality of BNRThin by collaborating with Kim Hee-sun, who is well-known in China, and numerous local influencers (wanghong). Additionally, the exclusive advertising contract with Kim Hee-sun, has been expanded to cover not only China but also Hong Kong and Taiwan. The company stated that it plans to gradually respond to demand in the Greater China region based on this entry into China. Considering the nature of social commerce, where initial customer reactions are crucial, the company added that aggressive and extensive promotions are also planned.
BNRThin has established itself as the No.1 diet probiotic in the global market, being recognized for its product efficacy by competitive domestic consumers. AceBiome achieved remarkable growth from 1.83 million USD in sales in 2018 to 195.42 million USD in 2023. The first half of 2024 saw a 31.9% increase compared to the previous year, with sales reaching 105.32 million USD. With the realization of Chinese sales in the second half, annual revenue in 2024 is expected to grow more robustly.
China, with the largest obese population in the world, continues to see growth in the related markets. The expansion into the Chinese market through Xiaohongshu is expected to increase AceBiome’s sales and profitability. According to the Korea Trade-Investment Promotion Agency (KOTRA), the Chinese probiotics market is projected to grow from 15 billion USD in 2022 to 21 billion USD by 2025.
A company representative mentioned, “This entry into the Chinese market will be a catalyst for AceBiome’s global expansion. We plan to widely promote the superior efficacy of BNRThin through extensive marketing and engage with more consumers in China,” adding that “BNRThin is a product with proven functionality through human application tests conducted on Asians, and we are confident it will receive great acclaim in China.”